Ciprocopan (NXP100) Receives Marketing Approval in China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
NVCT•China marketing approval for Ciprocopan
- Nuvectis Pharma Inc. NVCT.O said Ciprocopan (NXP100) has received marketing approval in China for the treatment of patients with PNH previously untreated with complement inhibitors.
Source text: ID:nGNEbzjFWZ
Further company coverage: NVCT.O
